Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501267 · ClinicalTrials.gov registry record · Phase 1
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
A Phase 1 study of Overactive Bladder, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00501267 is a Phase 1 study of Overactive Bladder that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants, below the 211-participant average among 45 other Overactive Bladder trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00501267, a Phase 1 study of Overactive Bladder, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together
Conditions Studied
Interventions
- DRUG solabegron and oxybutynin
Study Locations (1)
Washington
- GSK Investigational Site - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501267
The ClinicalTrials.gov registry entry for NCT00501267 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 45 other Overactive Bladder trials with a reported enrollment target (89% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 1 intervention - of which solabegron and oxybutynin is the first listed.
NCT00501267 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00501267 about?
NCT00501267 is a clinical study titled "A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder". The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together
What is the current status of trial NCT00501267?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-06. Estimated completion is 2007-08.
What conditions does trial NCT00501267 study?
This clinical trial studies the following conditions: Overactive Bladder.
What interventions are being tested in trial NCT00501267?
The interventions under investigation include: solabegron and oxybutynin (DRUG).
Who is sponsoring clinical trial NCT00501267?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00501267 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced-dose Botox for Urgency Incontinence Among Elder Females
ACTIVE NOT RECRUITING · Phase 1
-
Botulin-A Toxin Instillations and Overactive Bladder
COMPLETED · Phase 1
-
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
COMPLETED · Phase 1
-
Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB
COMPLETED · Phase 1
-
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
RECRUITING · NA
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.